Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.63 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.52 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12355112 | 0.83 | CYP19A1 (0.71) | CYP19A1CYP11B2CYP17A1 | |
| SCHEMBL7944637 | 0.77 | CYP11B2 (1.00) | CYP19A1CYP11B2SMN1; SMN2CYP17A1 | |
| SCHEMBL1479951 | 0.69 | CYP19A1 (0.56) | CYP19A1CYP11B1HSD17B1LMNAMAPT | |
| SCHEMBL16944438 | 0.67 | HTR2C (0.64) | CYP19A1HSD17B1LMNAMAPTRECQL | |
| SCHEMBL31525384 | 0.67 | HTR2C (0.64) | CYP19A1HSD17B1LMNAMAPTRECQL | |
| SCHEMBL8068811 | 0.67 | HTR2C (0.64) | CYP19A1HSD17B1LMNAMAPTRECQL | |
| SCHEMBL30563632 | 0.66 | DRD2 (0.58) | CYP19A1HSD17B1LMNAMAPTRECQL | |
| SCHEMBL22516687 | 0.66 | CYP19A1 (0.52) | CYP19A1HSD17B1LMNAMAPTRECQL | |
| SCHEMBL607389 | 0.66 | CYP19A1 (0.52) | CYP19A1LMNAHTR2C | |
| SCHEMBL5498315 | 0.66 | CYP19A1 (0.52) | CYP19A1HSD17B1LMNAMAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190247-A1 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR | SCHERING CORPORATION (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010017120-A1 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR | SCHERING CORPORATION (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190247-A1 | CYCLOPROPYLCHROMENE DERIVATIVES AS MODULATORS OF THE ALPHA-2C RECEPTOR | ADRA2C, ADRB2, ADRA2A | CYP19A1 677/4885CYP11B2 43/4885CYP11B1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.